Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Monoamine Oxidase Inhibitor
Harmol is a β-carboline alkaloid functioning as a monoamine oxidase inhibitor and TFEB activator. It has been shown to induce cell mitosis, autophagy, and apoptosis, promoting the degradation of α-synuclein through the autophagy-lysosomal pathway. Harmol exhibits notable anti-tumor, anti-depressant, and anti-aging properties and demonstrates efficacy in improving motor impairments in models of Parkinson's disease. This compound holds significant potential for research in neurodegenerative diseases and cellular autophagy mechanisms. -
MitoNEET Agonist /MAO-B Inhibitor
TT01001 is a selective and orally active mitoNEET agonist and monoamine oxidase B (MAO-B) inhibitor, with an IC50 of 8.84 μM. It functions by preventing mitoNEET-mediated mitochondrial dysfunction, thus attenuating oxidative stress and neuronal apoptosis. TT01001 has demonstrated potential in improving type II diabetes and enhancing mitochondrial function in murine models. This compound is suitable for research focused on type II diabetes and neurological disorders. -
Monoamine Oxidase Inhibitor
Harmol hydrochloride is a potent monoamine oxidase inhibitor that functions as a transcription factor EB (TFEB) activator. It demonstrates significant biological activities, including the induction of cell mitosis, autophagy, and apoptosis. Additionally, Harmol hydrochloride promotes the degradation of α-synuclein by modulating the autophagy-lysosomal pathway, making it relevant in studies of neurodegenerative diseases. Its diverse pharmacological effects also extend to anti-tumor, anti-depressant, and anti-aging activities, and it has shown promise in alleviating motor impairments in models of Parkinson's disease. -
Monoamine Oxidase Inhibitor
4-Hydroxyderricin is a selective inhibitor of Monoamine Oxidase B (MAO-B) with an IC50 of 3.43 μM, making it a valuable tool for studying neurological conditions. In addition to its primary mechanism, it exhibits mild inhibition of dopamine β-hydroxylase activity. This compound has demonstrated a range of biological activities, including antidepressant, anti-allergic, anti-diabetic, antioxidant, and antitumor effects. It has been shown to induce apoptosis and cell cycle arrest in hepatocellular carcinoma cells via modulation of the PI3K/AKT/mTOR pathway, as well as enhance osteoblast differentiation while inhibiting osteoclast formation, positioning it as a promising candidate for research into inflammatory diseases. -
HSP90/MAO-A inhibitor
MAO A/HSP90-IN-2 is a dual inhibitor targeting HSP90 and MAO A, exhibiting IC50 values of 0.016 μM and 4.58 μM, respectively. This compound enhances HSP70 expression while concurrently decreasing HER2, phospho-Akt, and IFN-γ induced PD-L1 levels in GL26 cells. It effectively inhibits the growth of both Temozolomide-sensitive and resistant glioblastoma cells, alongside other cancer types such as colon cancer, leukemia, and non-small cell lung cancer. MAO A/HSP90-IN-2 shows promise in addressing tumor immune evasion, making it a valuable tool for cancer research. -
MAO A/HSP90 Inhibitor
MAO A/HSP90-IN-1 is a dual inhibitor targeting MAO A and HSP90, exhibiting IC50 values of 1.77 μM in glioblastoma GL26 cells and 0.019 μM for HSP90α. This compound effectively inhibits MAO A activity, disrupts HSP90 binding, and downregulates HER2 and phospho-Akt expression, leading to reduced growth of glioblastoma cells. Additionally, MAO A/HSP90-IN-1 decreases PD-L1 expression, which may hinder tumor immune escape and suppress T cell activation. This reagent serves as a valuable tool for research on brain tumor-related diseases. -
PTP1B/hMAO-A Inhibitor
Cassiaside B2 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) and human monoamine oxidase A (hMAO-A). This compound exhibits significant antiallergic properties and functions as a 5-HT2C receptor agonist. It serves as a valuable tool for understanding the modulation of these targets in various biological pathways and contributes to research in neuropharmacology and allergy-related studies. -
MAO-B/Acetylcholinesterase Inhibitor
MAO-B-IN-26 is a selective inhibitor of monoamine oxidase B (MAO-B) and acetylcholinesterase, demonstrating neuroprotective properties against β-amyloid (Aβ) induced cytotoxicity in SH-SY5Y cells. This compound effectively mitigates morphological alterations, reactive oxygen species (ROS) generation, and membrane damage associated with neurodegeneration. Additionally, MAO-B-IN-26 suppresses Aβ-induced autophagy and apoptosis, making it a valuable tool for research focused on therapeutic strategies for Alzheimer's disease. -
MAO-A/DYRK1A Inhibitor
Norharmine is a Harmine analogue that functions as an inhibitor of monoamine oxidase A (MAO-A) and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). It exhibits weak inhibitory activity against MAO-A and demonstrates certain inhibitory effects on DYRK1A, positioning it as a valuable tool for research in neurobiology and cellular signaling pathways. Norharmine is useful in studies focusing on mood disorders and cognitive functions related to these kinase targets. -
Monoamine Oxidase Inhibitor
Nialamide hydrochloride is a non-selective monoamine oxidase (MAO) inhibitor. It effectively inhibits MAO, regulating reactive oxygen species (ROS) production and influencing various physiological responses. This compound induces hyperkinesis in animal models, enhances the anticonvulsant effects of Diphenylhydantoin in mice, and increases rectal temperature while augmenting the pressor response to Norepinephrine. Nialamide hydrochloride is valuable in research focused on depression, inflammatory diseases, neurodegenerative disorders, and hypertension. -
hMAO-B Inhibitor
CHBO4 is a potent, reversible, competitive inhibitor of human monoamine oxidase B (hMAO-B), with an IC50 value of 0.031 μM and a Ki value of 0.010 ± 0.005 μM. This compound demonstrates the ability to reduce cell damage by scavenging intracellular reactive oxygen species (ROS). CHBO4 is suitable for research applications focused on Parkinson's disease (PD) and related neurodegenerative conditions. -
MAO-B Inhibitor
MAO-B-IN-7 is a selective inhibitor of monoamine oxidase B (MAO-B) and acetylcholinesterase (AChE), demonstrating IC50 values of 41 nM for human AChE, 87 nM for electric eel AChE, and 0.3 μM for MAO-B. This compound is notable for its ability to penetrate the blood-brain barrier, making it suitable for central nervous system research. MAO-B-IN-7 has been shown to mitigate oxidative stress and neuroinflammation, supporting its potential applications in neurodegenerative disease studies. -
MAO-B Inhibitor
MAO-B-IN-54 is a selective, reversible, and competitive inhibitor of monoamine oxidase B (MAO-B), exhibiting a human IC50 of 0.052 μM and a Ki of 0.028 μM. This compound demonstrates minimal activity against MAO-A and effectively binds to both the entrance and substrate cavity of MAO-B, establishing hydrophobic and hydrogen bonding interactions. MAO-B-IN-54 has been shown to inhibit amyloid-beta (Aβ) aggregation and reduce reactive oxygen species (ROS) production, making it a valuable tool for research into Alzheimer's disease mechanisms. -
MAO-B Inhibitor
Sembragiline is a potent and selective reversible inhibitor of monoamine oxidase B (MAO-B). By inhibiting MAO-B activity, Sembragiline decreases the metabolism of dopamine and other amine neurotransmitters, potentially increasing their levels within the brain. This inhibition also reduces the formation of toxic reactive oxygen species (ROS), which are implicated in the pathology of Alzheimer's disease (AD). Sembragiline demonstrates favorable oral bioavailability and effective permeability across the blood-brain barrier, making it a valuable tool for research on AD, particularly in patients exhibiting elevated MAO-B activity. -
MAO-B Inhibitor
MAO-B-IN-49 is a selective and reversible inhibitor of monoamine oxidase B (MAO-B), with an impressive IC50 of 1 nM for human MAO-B and minimal activity against MAO-A (IC50 = 633.9 μM). This compound effectively reduces reactive oxygen species (ROS) production in HT22 cells, demonstrating substantial neuroprotective effects. In preclinical models of Parkinson's disease, MAO-B-IN-49 significantly mitigates motor dysfunction in MPTP-induced mice, making it a valuable reagent for studying neurodegenerative disorders and their underlying mechanisms. -
MAO-B Inhibitor
Multi-target kinase-IN-10 is a selective and reversible inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 of 0.0053 μM. This compound effectively penetrates the blood-brain barrier and competitively binds to the active site of MAO-B, disrupting substrate interactions. By chelating Cu2+ ions, it inhibits copper-induced reactive oxygen species (ROS) production and decreases the release of pro-inflammatory cytokines such as NO, TNF-α, and IL-1β. Multi-target kinase-IN-10 holds potential for therapeutic applications in the treatment of Parkinson's disease. -
MAO-A Inhibitor
Azure B is a potent and selective reversible inhibitor of monoamine oxidase A (MAO-A), exhibiting IC50 values of 11 nM for recombinant human MAO-A and 968 nM for MAO-B. As the major metabolite of Methylene blue, Azure B plays a crucial role in the synthesis of Azure eosin stains, commonly used for blood smear staining. This compound also demonstrates significant antidepressant-like effects, making it a valuable reagent for research in neuropharmacology and the study of mood disorders. -
MAO-A/B Inhibitor
Tedizolid phosphate sodium is a selective inhibitor of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). This compound exhibits significant activity against Gram-positive bacteria, making it valuable in the study of antimicrobial resistance and the development of new therapeutic agents. Its mechanisms of action and inhibition properties facilitate research into neurological disorders and other conditions associated with monoamine dysregulation. -
MAO Inhibitor
Eckol is a potent inhibitor of human monoamine oxidase A (hMAO-A) and a non-competitive inhibitor of human monoamine oxidase B (hMAO-B), with IC50 values of 7.20 μM and 83.44 μM, respectively. This compound exhibits significant biological activity through its antiallergic and antiviral effects, making it a valuable tool for exploring these pathways. Additionally, Eckol promotes stimulatory effects in maize and may serve as an effective plant biostimulant in agricultural research applications. -
MAO-A/5-HT2AR Inhibitor
MAO-A/5-HT2AR-IN-1 is a potent dual inhibitor of monoamine oxidase A (MAO-A) and serotonin receptor 2A (5-HT2AR), exhibiting IC50 values of 0.004 μM and 0.014 μM, respectively. This compound demonstrates significant potential in the field of antidepressant research, contributing to the modulation of serotonin levels and receptor activity. It is a valuable tool for investigating the pharmacological impact of MAO-A and 5-HT2AR inhibition in neuropsychiatric disorders. -
MAO Inhibitor
9-Methyl-β-carboline is a potent monoamine oxidase (MAO) inhibitor, demonstrating an IC50 of 1 μM for human MAO-A and 15.5 μM for human MAO-B. This compound shows significant potential for cognitive enhancement by increasing dopamine levels through its inhibition of MAO activity and modulation of microglial proliferation. Additionally, 9-Methyl-β-carboline activates signaling pathways such as PKA/PKC and influences mitochondrial respiratory function, contributing to neuroprotection and the reduction of α-synuclein levels. It is particularly relevant in research focusing on Parkinson's disease, given its neurotrophic effects and ability to counteract neurotoxin-induced dopaminergic neuron damage. -
MAO Inhibitor
Harmane hydrochloride is a monoamine oxidase (MAO) inhibitor that exhibits multiple biological activities. It demonstrates significant inhibition of MAO-A and MAO-B, with IC50 values of 0.5 μM and 5 μM, respectively. This compound has been shown to possess antidepressant, anti-anxiety, anticonvulsant, and analgesic properties, making it valuable in neuropharmacological research. Additionally, Harmane hydrochloride can influence tyrosine hydroxylase activity, impacting dopamine biosynthesis and enhancing cytotoxicity induced by L-DOPA in in vitro models. Its mutagenic potential is also notable, particularly in conjunction with 2-acetylaminofluorene. -
MAO-B Inhibitor
Monoamine Oxidase B Inhibitor 6 is a highly selective, reversible, and competitive inhibitor of monoamine oxidase B (MAO-B) with a significant brain-blood barrier penetration capability, exhibiting an IC50 of 0.11 μM. This compound demonstrates notable antioxidant and neuroprotective properties and is applicable in the study of neurodegenerative diseases. Researchers investigating the role of MAO-B in neurobiology may find it a valuable tool for elucidating mechanisms of disease and exploring therapeutic avenues. -
MAO-A Inhibitor
Pirlindole mesylate is a selective and reversible inhibitor of monoamine oxidase A (MAO-A), playing a crucial role in the modulation of neurotransmitter metabolism. Additionally, Pirlindole exhibits antiviral activity against enterovirus D68 and coxsackievirus B3 (CV-B3), positioning it as a potential agent in virology research. This compound is valuable for studies focusing on depression, anxiety disorders, and the therapeutic mechanisms of neuronal regulation and viral infections. -
A2AAR/hMAO-B Inhibitor
A2AAR/hMAO-B-IN-1 is a non-xanthine dual-target inhibitor that selectively inhibits the A2A adenosine receptor (A2AAR) with an IC50 of 34.9 nM, and human monoamine oxidase B (MAO-B) with a Ki of 39.5 nM. The compound effectively disrupts A2AAR-mediated cAMP accumulation and demonstrates competitive, reversible inhibition of MAO-B. A2AAR/hMAO-B-IN-1 is suitable for research applications in neurodegenerative diseases, particularly in the study of Parkinson's disease (PD). -
MAO A Inhibitor
MD 770222 is a selective and reversible inhibitor of monoamine oxidase A (MAO A). As a major O-demethyl metabolite of Cimoxatone, it exhibits notable inhibitory activity, albeit with reduced potency compared to its parent compound. This reagent is valuable in research focused on neurotransmitter modulation, neuropsychiatric disorders, and the understanding of MAO A's role in various biological processes. -
ALDH-2/MAO Inhibitor
7-Hydroxy-4-phenylcoumarin is a dual inhibitor of aldehyde dehydrogenase-2 (ALDH-2) and monoamine oxidase (MAO), demonstrating IC50 values of 1.5 µM and 0.5 µM, respectively. This compound exhibits significant biological activity that may influence cellular metabolism and neurotransmitter regulation. It is suitable for research applications focused on neuroprotection and metabolic studies. -
MAO Inhibitor
MAO-B-IN-46 is a selective inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 of 26.8 nM, exhibiting weak inhibition of hMAO-A (IC50: 7.2054 μM). This compound also functions as an α-amylase inhibitor, presenting an IC50 of 19.46 μM. Its neuroprotective properties demonstrate the potential for investigating neurodegenerative conditions such as Parkinson's disease, while its ability to scavenge DPPH and ABTS free radicals (IC50 values of 17.86 μM and 17.71 μM, respectively) highlights its relevance in research related to oxidative stress and diabetes. MAO-B-IN-46 shows minimal toxicity to human gingival fibroblasts and SH-SY5Y cells. -
CA/MAO-B Inhibitor
CA/MAO-B-IN-1 is a potent dual inhibitor of human brain carbonic anhydrases (CA) and Monoamine Oxidase-B (MAO-B), exhibiting IC50 values of 8.8 nM and 7.0 nM, respectively. This compound demonstrates significant potential for research applications related to neurological conditions, as it may modulate both enzymatic activity and associated pathways. Additionally, in silico predictions suggest favorable oral absorption of 71.9%, making it a relevant candidate for further pharmacological studies. -
hMAO-B/MB-COMT Inhibitor
hMAO-B/MB-COMT-IN-1 is a dual inhibitor of human monoamine oxidase B (hMAO-B) and membrane-bound catechol-O-methyltransferase (MB-COMT), exhibiting IC50 values of 2.5 µM and 3.84 µM, respectively. This compound is effective in protecting cells from oxidative damage, making it a valuable tool for studying neurodegenerative diseases, including Parkinson's Disease. Its dual inhibition profile provides insights into the molecular mechanisms underlying these conditions and aids in the development of potential therapeutic strategies. -
hMAO-B/MB-COMT Inhibitor
hMAO-B/MB-COMT-IN-2 is a potent dual inhibitor of hMAO-B and MB-COMT, exhibiting IC50 values of 4.27 μM and 2.69 μM, respectively. This compound effectively protects cells from oxidative damage, making it valuable for studies related to neurodegenerative diseases. hMAO-B/MB-COMT-IN-2 is particularly relevant in the research of conditions such as Parkinson’s Disease, offering insights into potential therapeutic strategies. -
CYP2A6/MAO Inhibitor
8α-(2-Methylacryloyloxy)-hirsutinolide-13-O-acetate functions as an irreversible inhibitor of CYP2A6, exhibiting IC50 values of 8.64 μM and 22.3 μM under pre-incubation and co-incubation conditions, respectively. Additionally, this compound demonstrates inhibitory activity against monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), with IC50 values of 60.2 μM and 38.6 μM, respectively. It serves as a valuable tool for research involving drug metabolism, neurochemistry, and the study of pharmacological responses influenced by these metabolic pathways. -
5-LOX/MAO Inhibitor
5-LOX/MAOs-IN-1 is a dual inhibitor of 5-lipoxygenase (5-LOX) and monoamine oxidases (MAOs), exhibiting potent antioxidant properties through free radical scavenging. This compound demonstrates neuroprotective effects in cell models subjected to oxidative stress and promotes a supportive microenvironment for neurogenesis in adult mouse neural stem cells. 5-LOX/MAOs-IN-1 is suitable for research focused on neurodegenerative diseases and mechanisms of neuroprotection. -
MAO Inhibitor
Norharmane is a reversible monoamine oxidase (MAO) inhibitor, exhibiting IC50 values of 6.5 μM for MAO-A and 4.7 μM for MAO-B. This β-carboline alkaloid demonstrates potential antidepressant effects and may act as an anti-cancer photosensitizer. Additionally, Norharmane has been shown to inhibit polar auxin transport by targeting the PIN2, PIN3, and PIN7 transport proteins, resulting in significant growth suppression of Arabidopsis thaliana seedlings. -
Monoamine Oxidase Inhibitor
(S)-Salsolidine is a weak inhibitor of monoamine oxidase (MAO), exhibiting a Ki value of 63 μM. This compound may be utilized in research to explore the role of MAO in various neurological conditions. Its activity supports investigations into the biochemical pathways involving monoamines, providing insights into potential therapeutic applications in mood disorders and related diseases. -
MAO-B Inhibitor
MAO-B-IN-9 is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) that effectively penetrates the blood-brain barrier, exhibiting an IC50 of 0.18 μM. This compound demonstrates neuroprotective effects by preventing Aβ1-42-induced neuronal cell death, potentially through its ability to inhibit Aβ1-42 aggregation. Additionally, MAO-B-IN-9 serves as a click chemistry reagent, featuring an alkyne group that readily participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions for versatile applications in chemical biology research. -
MAO-B Inhibitor
MAO-B-IN-10 is a selective monoamine oxidase B (MAO-B) inhibitor with a potent IC50 of 5.3 μM. It effectively inhibits and disaggregates amyloid β (Aβ) aggregation, achieving 58.2% inhibition and 43.3% disaggregation of self-mediated Aβ. This compound is valuable for research related to Alzheimer's disease, offering insights into the modulation of Aβ aggregation in neurodegenerative processes. -
MAO-B Inhibitor
MAO-B-IN-50 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 value of 0.06 μM. This compound is effective in inhibiting the aggregation of amyloid-beta (Aβ40/42) and Tau proteins, with overall IC50 values near 1 μM. Additionally, MAO-B-IN-50 shows potent selective inhibition of acetylcholinesterase (AChE) with an IC50 of 1.78 μM. It is suitable for use in research related to Alzheimer's disease. -
AChE/MAO-B Inhibitor
AChE/MAO-B-IN-9 is a selective, reversible, non-competitive inhibitor of acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B), exhibiting an IC50 of 0.156 μM against electric eel AChE. This compound effectively inhibits the formation of Aβ40/42 fibrils, promotes the depolymerization of Aβ fibrils, and suppresses Tau protein fibril formation. Additionally, AChE/MAO-B-IN-9 demonstrates antioxidant and neuroprotective properties, while alleviating memory deficits induced by scopolamine in murine models. This reagent is valuable for research related to Alzheimer’s disease. -
Dual MAO/AChE Inhibitor
Ladostigil hemitartrate is a dual inhibitor of monoamine oxidase (MAO) and acetylcholinesterase (AChE), with established IC50 values of 37.1 μM for MAO-B and 31.8 μM for AChE. This compound is capable of crossing the blood-brain barrier and exhibits neuroprotective, antioxidant, and anti-inflammatory properties. Ladostigil hemitartrate is relevant for research into neurological disorders, including depression and Alzheimer's disease. Additionally, it functions as a click chemistry reagent, featuring an alkyne group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
MAO/AChE Inhibitor
Ladostigil hydrochloride is a potent dual inhibitor of acetylcholinesterase (AChE) and monoamine oxidase-B (MAO-B), exhibiting IC50 values of 37.1 µM and 31.8 µM, respectively. This compound demonstrates neuroprotective, antioxidant, and anti-inflammatory properties, making it valuable for research related to depression and Alzheimer's disease. Additionally, Ladostigil hydrochloride functions as a click chemistry reagent, featuring an alkyne group that can participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating diverse chemical applications. -
Dual MAO and AChE Inhibitor
Ladostigil is a dual inhibitor of monoamine oxidase (MAO) and acetylcholinesterase (AChE), demonstrating IC50 values of 37.1 μM for MAO-B and 31.8 μM for AChE. This compound exhibits neuroprotective, antioxidant, and anti-inflammatory properties, making it valuable for research in conditions such as depression and Alzheimer's disease. Additionally, Ladostigil features an alkyne functional group, enabling it to serve as a click chemistry reagent through copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
MAO Inhibitor
ASS234 is a potent monoamine oxidase (MAO) inhibitor, targeting MAO-A and MAO-B with IC50 values of 5.2 nM and 43 nM, respectively. In addition to its primary activity, ASS234 also exhibits inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), with IC50 values of 350 nM and 460 nM, respectively. This compound can be utilized in research related to neurodegenerative diseases, mood disorders, and cholinergic signaling pathways. -
AChE-MAO B Inhibitor
Dual AChE-MAO B-IN-2 is a powerful inhibitor of both acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), exhibiting IC50 values of 0.12 µM and 0.01 µM, respectively. This dual inhibition profile suggests its significant potential in the study and development of therapeutic strategies for Alzheimer's disease. Researchers can utilize Dual AChE-MAO B-IN-2 to explore mechanisms related to cholinergic dysfunction and oxidative stress in neurodegenerative conditions. -
ChEs/MAOs Inhibitor
ChEs/MAOs-IN-2 is a potent inhibitor of cholinesterases and monoamine oxidases, exhibiting IC50 values of 0.10 µM for MAO-A, 0.20 µM for MAO-B, 0.30 µM for acetylcholinesterase (AChE), and 0.40 µM for butyrylcholinesterase (BChE). This compound demonstrates significant biological activity relevant to neurodegenerative diseases, particularly Alzheimer's disease, and serves as a valuable tool for research into therapeutic strategies targeting these enzymes. -
ChE/MAO-A Inhibitor
Desoxypeganine is a potent alkaloid that serves as an inhibitor of cholinesterase (both BChE and AChE) as well as a selective inhibitor of monoamine oxidase A (MAO-A), exhibiting IC50 values of 2, 17, and 2 μM, respectively. This compound is primarily utilized in research related to alcohol abuse, offering valuable insights into the underlying mechanisms of addiction and potential therapeutic approaches. Its dual inhibitory action positions Desoxypeganine as a significant tool in the study of neurochemical pathways involved in substance use disorders. -
AChE/BChE/MAO-B Inhibitor
AChE/BChE/MAO-B-IN-5 is a multitarget inhibitor of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase B (MAO-B). With IC50 values of 0.24 µM, 6.29 µM, and 0.11 µM for AChE, BChE, and MAO-B, respectively, this compound demonstrates potent inhibition of key enzymes involved in cholinergic neurotransmission and monoamine metabolism. AChE/BChE/MAO-B-IN-5 is particularly relevant for research into neurodegenerative diseases, including Alzheimer's disease, due to its ability to penetrate the blood-brain barrier. -
AChE/BuChE/MAO-B Inhibitor
AChE/BuChE/MAO-B-IN-1 is a potent inhibitor of human acetylcholinesterase (hAChE), butyrylcholinesterase (hBuChE), and monoamine oxidase-B (hMAO-B), with IC50 values of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. This compound also demonstrates a high affinity for σ1 and σ2 receptors, with Ki values of 42.8 nM and 191 nM, respectively. AChE/BuChE/MAO-B-IN-1 is potentially useful in research focused on Alzheimer's disease and related neurological disorders. -
AChE/BChE/MAO-B Inhibitor
AChE/BChE/MAO-B-IN-1 is a reversible inhibitor targeting acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase B (MAO-B), exhibiting IC50 values of 7.31 μM, 0.56 μM, and 26.1 μM, respectively. This compound effectively crosses the blood-brain barrier and demonstrates neuroprotective properties while maintaining a lack of cytotoxicity. Its multifaceted inhibition profile makes it a valuable tool for research on neurodegenerative diseases and associated pathways.
